Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Prilenia Therapeutics B.V.

Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress
From Prilenia Therapeutics B.V.
Via Business Wire
Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting
From Prilenia Therapeutics B.V.
Via Business Wire
Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 Congress
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington’s Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual Meeting
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer
From Prilenia Therapeutics B.V.
Via Business Wire
SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Announces Completion of Patient Enrollment Ahead of Schedule in the Pridopidine Arm of the HEALEY ALS Platform Trial
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Receives Fast Track Designation for Pridopidine for the Treatment of Huntington’s Disease
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia Closes Oversubscribed $43 Million in Series B Financing Round
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia and Huntington Study Group Announce Completion of Patient Enrollment Ahead of Schedule in Global Phase 3 PROOF-HD Huntington’s Disease Clinical Trial
From Prilenia Therapeutics B.V.
Via Business Wire
Prilenia receives positive EMA opinion on Orphan Drug Designation for pridopidine in ALS
From Prilenia Therapeutics B.V.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.